This report analyzes the merger and acquisition (M&A) activity in Q4 2024 in the Pharma sector.
The global pharma sector in Q4 2024 witnessed deals worth $18.5 billion, a decline of 31.9% compared to Q3 2024. In terms of deal volume, there was a rise of 7.5% to 144 M&A deals in Q4 2024. Oncology was the top therapy area with 51 deals, an increase of 4.1% YoY compared to 2023.
The global pharma sector in Q4 2024 witnessed deals worth $18.5 billion, a decline of 31.9% compared to Q3 2024. In terms of deal volume, there was a rise of 7.5% to 144 M&A deals in Q4 2024. Oncology was the top therapy area with 51 deals, an increase of 4.1% YoY compared to 2023.
Scope
- This report provides an overview of M&A activity globally in Q4 2024 in the Pharma sector involving biopharmaceutical drug companies.
- It identifies key trends, and the most notable deals announced in Q4 2024 in the Pharma sector.
Reasons to Buy
- Companies that make strategic investments in M&A position themselves for success, while those that fail to adapt risk falling behind.
- This report provides an overview of global M&A trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Table of Contents
1 Table of Contents1.1 List of Tables
1.2 List of Figures
2 Pharma M&A Activity in Q4 2024
2.1 Pharma Insights: Deal spotlight
3 Global M&A Trends in Pharma
4 Global Quarterly M&A Activity in Pharma
5 Ownership Type: Private Vs Public (Count)
6 Ownership Type: Private Vs Public (Value)
7 Global M&A Activity in Pharma by Deal Size
8 Notable Pharma Deals in Q4 2024
9 Pharma Regional Comparison - Q4 2024
10 Global Cross Border M&A Trends in Pharma
11 Inbound and Outbound Deals in Pharma in Q4 2024
12 Regional M&A Activity in Pharma by Value and Volume
13 Pharma M&A Review by Top 10 Countries
14 Top 10 Therapy Area M&A Review
16 Further Information
16.1 Methodology
17 Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- F. Hoffmann-La Roche
- AbbVie
- Merck & Co
- Ampersand Capital Partners; GHO Capital Partners
- Novartis
- BioNTech
- GSK
- Longboard Pharmaceuticals
- Synthon International Holdings
- Poseida Therapeutics
- Aliada Therapeutics
- Modifi Biosciences
- Avid Bioservices
- Kate Therapeutics
- Biotheus
- Torrent Pharmaceuticals
- Relation Therapeutics
- H. Lundbeck
